SCHEMBL3336020

SCHEMBL3336020

Nc1nc(OC2CCCC2)c2cc(Br)ccc2n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 1/20 0.42
ADORA2A P29274 2/20 0.42
BCHE P06276 5/20 0.42
ACHE P22303 5/20 0.42
GRIN1 Q05586 5/20 0.42
GRIN2A Q12879 5/20 0.42
HTT P42858 1/20 0.40
PTGES O14684 1/20 0.40
PABPC1 P11940 1/20 0.40
POLB P06746 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HRH4 Q9H3N8 1/20 0.36
JAK3 P52333 2/20 0.35
ADRB2 P07550 1/20 0.35
ADORA3 P0DMS8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340857 0.83 IRAK4 (0.43) IRAK4ADORA2ABCHEACHEGRIN1
SCHEMBL3335725 0.79 MAP4K4 (0.41) ADORA2A
SCHEMBL3331706 0.77 CDK2 (0.48) ADORA2ABCHEACHEGRIN1GRIN2A
SCHEMBL3333468 0.77 CDK2 (0.44) ADORA2ABCHEACHEGRIN1GRIN2A
SCHEMBL3336097 0.76 PIK3CD (0.51)
SCHEMBL4359661 0.73 IRAK4 (0.51) IRAK4ADORA2ABCHEACHEGRIN1
SCHEMBL3335280 0.73 RXFP1 (0.43) IRAK4ADORA2ABCHEACHEGRIN1
SCHEMBL3337990 0.72 DHFR (0.49) ADORA2ABCHEACHEGRIN1GRIN2A
SCHEMBL3335868 0.72 ADORA2A (0.45) ADORA2ABCHEACHEGRIN1GRIN2A
SCHEMBL4367800 0.72 IRAK4 (0.50) IRAK4ADORA2ABCHEACHEGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 IRAK4 1560/4885ADORA2A 1968/4885BCHE 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.